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Summary
Lung transplantation is an established therapy for end-stage
pulmonary disorders in selected patients without signific-
ant comorbidities. The particular constraints associated
with organ transplantation from deceased donors involve
specific allocation rules in order to optimise the medical ef-
ficacy of the procedure. Comparison of different policies
adopted by national transplant agencies reveals that an op-
timal and unique allocation system is an elusive goal, and
that practical, geographical and logistic parameters must be
taken into account.
A solution to attenuate the imbalance between the number
of lung transplant candidates and the limited availability of
organs is to consider marginal donors. In particular, assess-
ment and restoration of gas exchange capacity ex vivo in
explanted lungs is a new and promising approach that some
lung transplant programmes have started to apply in clinic-
al practice.
Chronic lung allograft dysfunction, and especially bronchi-
olitis obliterans, remains the major medium- and long-term
problem in lung transplantation with a major impact on
survival. Although there is to date no cure for established
bronchiolitis obliterans, new preventive strategies have the
potential to limit the burden of this feared complication.
Unfortunately, randomised prospective studies are infre-
quent in the field of lung transplantation, and data obtained
from larger studies involving kidney or liver recipients are
not always relevant for this purpose.
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Introduction
With more than 32 000 procedures performed worldwide in
the last three decades, lung transplantation has become the
Abbreviations:
LAS Lung Allocation Score
SOAS Swiss Organ Allocation System
EVLP Ex vivo lung perfusion
BO(S) Bronchiolitis obliterans (syndrome)
DSA Donor specific antibody
standard of care for selected patients with advanced lung
diseases. However, short- and long-term survival are in-
ferior to those in other solid organ transplantation. Specific
challenges include higher perioperative mortality, a high-
er rate of acute and chronic rejection, and infections of the
transplanted graft which is in direct contact with open air.
In this review we focus on three issues that have a pro-
found impact on lung transplantation programmes around
the world: the system of lung allocation, new procedures
to evaluate suboptimal organs, and the challenge of chronic
lung allograft dysfunction.
Lung allocation
Legal and ethical perspective
Organ transplantation from deceased donors is a treatment
associated with specific constraints, there being a universal
shortage of donors compared to recipient candidates on the
waiting list. It is therefore a unique situation involving ex-
plicit rationing of therapy. To deal with this situation most
countries have developed a legal framework for alloca-
tion of organs from deceased donors, with a specific set of
rules for each organ (table 1). The allocation systems that
have been implemented throughout the world are always a
compromise between two antagonistic demands: patient’s
equity and medical efficacy. The patient’s equity principle
implies that no one should be discriminated against in or-
gan allocation because of age, gender, ethnicity and so-
cioeconomic status, physical or psychic characteristics.
The medical efficacy principle means that organ transplant-
ation should be offered to the recipient who will derive
maximum improvement of survival compared with con-
ventional standard care. A classical illustration of this di-
lemma encountered in the daily life of lung transplantation
teams is the “competition” between a young patient with
cystic fibrosis and a 60-year-old ex-smoker with end-stage
COPD. Which of them will receive transplant of the lungs
from a 55-year-old donor?
Practical solutions
Several allocation systems have been devised to solve this
transplantation dilemma [1–3]: historically most trans-
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plantation centres have started their programme with loc-
ally based allocation: it was the surgeon who made the
choice, in the middle of the night, of the most befitting re-
cipients on the local waiting list. Although considered the
most simple and efficient method of resource allocation by
many, this method is no longer accepted by the health au-
thorities in some countries (e.g. Switzerland) because of
the lack of transparency and a theoretical proneness to non-
medical bias. Next, the easiest way to choose the right re-
cipient is chronological, that is, time spent on the waiting
list. This rule was applied in the USA until 2005 [1], and is
still in use in the Swiss Organ Allocation System (SOAS),
with some exceptions [3] (cf below): The major draw-
back of chronological allocation is that the risk of death
on the waiting list differs according to lung diseases, being
highest for idiopathic lung fibrosis and lowest for COPD.
Strict enforcement of the chronological rule would there-
fore run counter to the equity principle, since most patients
with lung fibrosis will die on the waiting list before re-
ceiving a transplant. For these reasons, several lung trans-
plantation agencies have implemented, on top of chrono-
logical allocation, some rules of priority, usually labelled
as urgent or super-urgent status (table 2). Urgent status
is usually defined by the severity of the disease or the
amount of care, but not by a specific diagnosis [4]. Al-
though mechanical ventilation in the ICU is the usual cri-
terion for urgent status, the other criteria differ significantly
within countries: for example, COPD and retransplantation
are exclusion criteria for urgency status in France, but not
in Eurotransplant or in the SOAS. Another consequence
of chronologically-based allocation is preemptive listing of
the patient and, therefore, a longer waiting time on the list
(table 1). The Swiss SOAS is basically a modified chrono-
logical system: a high priority urgent status is assigned to
patients treated with invasive mechanical ventilation in the
ICU. A second and third order of priority is assigned to pa-
tients with pulmonary arterial hypertension (PAH) and then
idiopathic lung fibrosis. Finally, at the lowest order of pri-
ority before chronological order, lungs from donors aged
below 40 are allocated preferentially to recipients <40. Ac-
cording to this system, the lungs from a 25-year-old donor
will be allocated first to a 60-year-old recipient with PAH,
then to a 30-year-old patient with cystic fibrosis.
Is a comparison between systems possible?
It is scientifically highly challenging to decide objectively
which is the best system. Every lung transplantation team
throughout the world will acknowledge some frustration in
the daily life of lung allocation in the context of a continu-
ously growing waiting list. Furthermore, objective com-
parison between systems is a difficult task: data are not
reported or even calculated in the same manner between
registries, and epidemiological together with geographical
considerations prevent side-to-side comparison. Local,
surgeon-based allocation, while allowing the greatest flex-
ibility, has the weakness of relying on a single individual’s
judgment. A strict chronological rule is unethical for pa-
tients with rapidly evolving disease. A chronological sys-
tem modified by some exceptions is always a compromise
within inherent rigidity, especially for less common lung
disorders. Theoretically, allocation based on medical effic-
acy and not on waiting time appears to be more appeal-
ing. This is the objective of the lung allocation score (LAS)
implemented in the USA since 2005 [5–7]. Based on data
continuously recorded and analysed from the UNOS re-
gistry, a score based on mortality risk on the waiting list,
combined with survival in the first year after transplant-
ation, allows the adult future recipient to be ranked on a
scale from 0 to 100. Clinical parameters, haemodynam-
ics and laboratory data are used to calculate the LAS. The
immediate impact of such a system is to dramatically de-
crease waiting time, there being no need to list the pa-
tient preemptively to allow him a reasonable chance of re-
ceiving a transplant. One may consider this change merely
artifactual, but for the patient it may be of clinical sig-
nificance since his quality of life may be affected by a des-
Table 1: Lung allocation systems in 4 different areas.
Allocation system LAS Eurotransplant Agence de la Biomédecine SOAS
Web page www.unos.org www.eurotransplant.org www.agence-biomedecine.fr www.swisstransplant.org
Country USA AU; GE; NL; BE; LU France Switzerland
References [6] [4] [52] [3]
Year of introduction 2005 NA 2007 2007
Main allocation rule Severity score High urgency and urgency
status
Local allocation Chronological; exceptions: ICU,
IPF, PAH
Urgent status Yes; review board Yes; predefined Yes, with expert panel Yes; predefined
Median waiting time (days) 148 195 135 208
% deaths on the waiting list 6.5 (yr 2008) 15.5 (yr 2009) 10.3 (yr 2009) 10.0 (2007–2009)
Number of lung tx/million / yr 4.5 6.1 (Germany)
7.2 (Belgium)
3.6 5.0
% lungs accepted 21 56 17 42
NA: not available; IPF: idiopathic pulmonary fibrosis; PAH: pulmonary arterial hypertension.
Table 2: Comparison of 3 European urgency statuses for lung transplantation.
Urgency criteria Eurotransplant Agence de la Biomédecine SOAS
Mechanical ventilation in the ICU Yes Yes Yes
COPD included Yes No Yes
Re-Tx included Yes No Yes
% of total candidates 40 17 10
SOAS: Swiss Organ Allocation System; Re-Tx: re-transplantation.
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perately long wait for an organ. On the other hand, while
the prediction of survival for lung candidates could be eval-
uated with reasonable accuracy, pre-transplantation predic-
tion of survival after transplantation is very poor [8–10].
Thus the LAS is essentially a pretransplant severity score.
This means that the most severely affected patients are
transplanted first, with the potential for higher perioperat-
ive morbidity and mortality due to these high-risk recipi-
ents. This has indeed been observed for recipients with the
highest quartile of the LAS score [9].
Despite these difficulties, what are the critical parameters
to consider for the evaluation of a lung transplantation pro-
gramme at the national level? In our opinion these should
include at least the number of transplants per million hab-
itants per year, the percentage of lung grafts transplanted
compared to identified donors, the percentage of deaths on
the waiting list and early and late post-transplant survival.
Periodic analysis of these data is of utmost importance in
devising policies of organ allocation.
Ex-vivo lung perfusion: a new tool for
donor organ assessment and
reconditioning before lung
transplantation
The lack of donor organs is a well-known major obstacle
to the treatment of benign end-stage lung disease by lung
transplantation. Two different approaches are currently be-
ing explored to enlarge the pool of donors: use of extended
criteria for selection of donor lungs [11] and lung pro-
curement from donors after cardiac death [12]. These new
strategies will hopefully increase the number of organs for
lung transplantation in the future, and both may change the
way potential donor lungs are managed before transplanta-
tion.
The donor organ is classically selected on the basis of
donor history, physical examination, bronchoscopy, blood
gas analysis and chest x-ray. An ideal donor lung is defined
by age below 55 years, a PaO2/FiO2 ratio >300 mm Hg, no
history of smoking or less than 20 pack-years, a clear chest
x-ray and no purulent tracheal secretions [13]. Assessment
of the potential donor lung is completed during procure-
ment surgery. To avoid harmful effects of brain death on
the lung, such as neurogenic oedema formation, potential
donor lungs are resuscitated by appropriate medical donor
management before organ retrieval [14]. Many transplant-
ation centres do not restrict lung procurement to ideal
donors, but have extended these criteria to so-called “mar-
ginal” lungs. Uncertainties remain, however, as to the ex-
tent to which these criteria can be widened. Nevertheless,
even with the most aggressive approach, more than 50% of
donors are considered unsuitable for lung donation (table
1). New concepts have been developed to enlarge the donor
pool:
Marginal grafts not fulfilling the standard criteria for lung
transplantation may undergo a so-called “pretransplant re-
conditioning” to render them suitable for transplantation.
As a result, graft assessment should take initial lung func-
tion into account, but should also judge the possible suitab-
ility of the organ for transplantation after reconditioning.
In this context, ex vivo lung perfusion (EVLP) is set to
evolve as a promising strategy: it may be applied (1.) to
assessing graft function after procurement and before im-
plantation, (2.) to preserving the graft after harvesting over
long time intervals, and (3.) to repairing potential grafts
which are initially considered inappropriate for transplant-
ation.
This new technique has been developed on the basis of pi-
oneer work by Steen et al. [15–18], in which explanted
lungs are perfused and ventilated in a closed ex-vivo circuit
(Ex-Vivo Lung Perfusion, EVLP; XVIVO®, Vitrolife,
Sweden). The lungs are perfused at a constant pressure be-
low 20 mm Hg with a buffered extracellular normotherm-
ic solution at an optimal colloid osmotic pressure (Steen
solution®, Vitrolife, Sweden), and are simultaneously vent-
ilated at low volume and pressure to avoid ventilation-in-
duced lung injury. During perfusion, several aerodynam-
ic (airway pressure, lung compliance) and haemodynamic
(pulmonary vascular resistance) measurements are done,
together with repeated blood gas analysis in the effluent
of the circuit. As a result, lungs can be properly evaluated
to determine their suitability for subsequent transplantation
[18].
Next to precise assessment of lung function, by ex vivo
perfusion of the explanted lung it is possible to protect the
donor organ from systemic effects of brain death. Recent
technical developments allow successful ex-vivo perfusion
for up to 12 hours without deterioration of the explanted
lungs’ physiological parameters [19, 20]. Interestingly, it
has been shown in experimental and clinical studies that the
functional status of marginal donor lungs can be improved
by EVLP to render them suitable for subsequent transplant-
ation, a process for which the term “reconditioning” has
been coined [15, 21]. Lung oedema can be eliminated dur-
ing the process of EVLP thanks to the hyperoncotic perfus-
ate, while atelectatic lung regions can be re-expanded by
the application of positive end-expiratory pressure in the
ventilation circuit. Pharmacological interventions are pos-
sible while the lung is perfused and ventilated in the EVLP
system, either by intravascular or endobronchial adminis-
tration of drugs: experimental studies indicate that inhaled
nitric oxide may reduce ischaemia-reperfusion injury [22],
and endobronchial application of surfactant was found to
reduce lung damage after acid aspiration [23]. Pulmonary
embolism was successfully treated by fibrinolytics [24] and
antibiotics may be added to the perfusion solution to treat
lung infection. Another experimental approach is trans-
bronchial ex-vivo gene therapy by EVLP: EVLP was used
to transfect lungs with an adenovirus encoding the antiin-
flammatory interleukin-10 [25]. EVLP was also applied to
clean the donor lung from pro-inflammatory cytokines by
inserting an adsorbing membrane in the circuit. In conclu-
sion, these different experimental studies show that EVLP
may at some point offer a specific graft repair opportunity,
depending on the type of donor lung injury, such as aspira-
tion, infection, atelectasis or oedema. A limited number of
human lung transplantations after EVLP have been repor-
ted to date [15, 21, 26, 27]. The largest and most recent one
was published by the Toronto group, reporting on 20 such
procedures from marginal donors. The authors concluded
that lung transplantations from high risk donors, with lungs
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exhibiting ex-vivo stability for 4 hours, have a similar out-
come to those obtained with conventionally selected lungs
[26]. These pilot studies are promising since they provide
first evidence that initially discarded human donor lungs
can be reconditioned to acceptable function and used for
transplantation with a satisfactory outcome.
In conclusion, ex vivo lung perfusion is a new technique
for functional assessment of donor organs, and may be ap-
plied in the future for specific repair of graft injury before
lung transplantation. EVLP can be used to recondition not
only marginal lungs from brain-dead donors, but also has
the potential for evaluation of lungs obtained from donors
after cardiac death. This may increase the number of avail-
able donor organs for lung transplantation in the future.
Further clinical studies are needed to establish the feasibil-
ity of this procedure.
Prevention and treatment of
bronchiolitis obliterans (BO) /
bronchiolitis obliterans syndrome
(BOS)
Definition and epidemiology
Bronchiolitis obliterans (BO) is the most prevalent form
of chronic lung allograft dysfunction (CLAD) and is the
leading cause of late mortality following lung transplanta-
tion [28]. BO is a progressive fibro-obliterative occlusion
process of the small airways triggered by lymphocytic in-
filtration of the submucosa resulting in epithelial cell nec-
rosis, mucosal ulcerations and formation of granulation tis-
sue. Because BO is difficult to document histologically, in
1993 a committee sponsored by the International Society
for Heart and Lung Transplantation proposed a clinical de-
scription of BO termed bronchiolitis obliterans syndrome
(BOS). These criteria were updated in 2001 and are now
defined by a sustained decrease in pulmonary function
parameters of ≥20% for FEV1 or FEF25-75 [29]. Radio-
graphic features suggestive of BOS include air trapping
and bronchiectasis, but are not highly sensitive. Currently
the incidence of BOS according to the ISHLT database is
49% at 5 years and 75% at 10 years [28].
The risk factors are immunological (acute graft rejection,
donor antigen-specific reactivity) and non-immunological
(viral-bacterial or fungal infections, primary graft dysfunc-
tion, gastrooesophageal reflux with aspiration, air pollu-
tion) [30, 31].
Recent research is directed at finding early markers of
BOS. Most of the markers identified to date are related to
chronic neutrophilic inflammation, such as exhaled nitric
oxide (eNO), chemokines and cytokines (IL-6, IL-8, il-10,
IL-15, KL-6 [28], RANTES) [32]. However, none of these
molecules has evidenced enough specificity to distinguish
infection from rejection.
Impact of the standard immunosuppressive regimen on
BOS prevalence
A few randomised controlled trials have been conducted to
compare the efficacy and adverse effects of cyclosporine
versus tacrolimus. In a meta-analysis conducted by Fan et
al., tacrolimus was found to be superior to cyclosporine for
the prevention of acute allograft rejection episodes [33].
However, the impact on BOS prevalence and survival was
not statistically significant.
In a monocentric prospective observational study, Speich
et al. found that mycophenolate mofetil compared to aza-
thioprine started from the first post-operative days signific-
antly decreased the incidence, severity and recurrence of
acute rejection episodes [34]. The incidence of graft loss
due to BO was reduced, although the incidence of BOS
and overall mortality was unchanged. A multicentric study
comparing the same immunosuppressants failed to show a
significant difference, although a higher rate of switches or
dropouts in the azathioprine arm was observed [35].
Rapamycin, also known as sirolimus, because of its anti-
fibroproliferative effect, may improve and/or stabilise the
decline of FEV1 but must be frequently withdrawn because
of adverse effects [36, 37].
Recently Vos et al. conducted an interesting prospective
randomised study by using the macrolide azithromycin to
prevent BOS after lung transplantation [38]. The rationale
for this trial was the known therapeutic effect of azithro-
mycin in neutrophilic BOS (cf. below). They demonstrated
a significant improvement of BOS-free survival among pa-
tients receiving azithromycin. The overall survival did not
differ between groups, but the follow-up may have been
too short to test this endpoint. On the basis of a single
monocentric study it is probably premature to introduce
azithromycin systematically to the regimen of every new
lung transplant recipient, but further reports involving this
strategy are awaited by the lung transplant community.
On the whole, very few randomised prospective studies
have been conducted and published with the incidence of
BOS as a specific aim (table 3).
Table 3: Randomised prospective trials for the prevention of BOS in lung transplantation.
Authors (ref.) Therapeutic action Endpoint Main results
Vos [38] Azithromycin BOS and survival at 2 yr Positive for BOS, negative for survival
Iacono [48] Inhaled CsA AR, survival Negative on acute rejection rate, but improvement
in survival
Palmer [53] MMF versus aza AR, survival at 6 months Negative
McNeil [35] MMF versus aza BOS at 3 yr Negative
Hachem [54] Tac versus CsA AR, BOS Positive in favour of Tac for AR, negative for BOS
Zuckermann [55] Tac versus CsA A AR, BOS, survival at 2 yr Negative
Bhorade [37] Sirolimus versus aza AR, BOS, survival at 1 yr Negative
Snell [56] Everolimus versus aza AR, BOS, survival at 1 and 2 yr Positive in favour of Everolimus at 1 yr, negative
at 2 yr
CsA: cyclosporine A; Aza: azathioprine; MMF: mycophenolate mofetil; Tac: tacrolimus; AR: acute rejection.
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Therapeutic strategies for established BOS
A few studies have described stabilisation of the decline
in FEV1 after conversion from cyclosporine to tacrolimus
[39–41]. Methotrexate has been used in a few patients
with recurrent acute rejection or BOS, and showed diminu-
tion of the decline in pulmonary function; however, it is
now rarely used because of severe side effects and toxicity
[42]. Attempts in the early years of lung transplantation
to reverse BOS by increasing the dosage of the immun-
osuppressive regimen have systematically failed and were
plagued by severe infectious complications.
In 2003 Gerhard et al. used the macrolide azithromycin for
the first time 3 times a week in a pilot study against BOS.
In five of their six patients FEV1 of 17.1% improved [43].
This study raised new hope for the control of BOS. Subse-
quent non-randomised studies have suggested that azithro-
mycin can alter the decline of FEV1 in about 35% of pa-
tients, particularly those with neutrophilia of ≥15% in the
bronchoalveolar lavage [44, 45].
In addition to a significant anti-inflammatory effect by
lowering the inflammatory mediators such as IL-17, IL-8,
IL-1β, TNF-α, RANTES, azithromycin also inhibits the
formation of Pseudomonas aeruginosa biofilm, flagellin
expression and adherence to the tracheal epithelium, and
may diminish gastrooesophageal reflux (GER) by enhan-
cing oesophageal motility and favouring gastric emptying
[45]. Although azithromycin is now widely used for pa-
tients with BOS in lung transplantation centres, controlled
prospective studies are awaited to strengthen the scientific
rationale for this.
Vanaudenaerde et al. proposed two clinical phenotypes of
BOS based on neutrophilic airway inflammation, clinical
status, time of onset, rapid progression, histology, and ra-
diology [45]. The immunological mechanism underlying
the development of these two phenotypes appears to be en-
tirely different. The NARD (neutrophilic reversible allo-
graft dysfunction) is triggered by repetitive mild injuries
such as infection, colonisation, GER and air pollution, and
will respond to azithromycin. The fBOS (fibroproliferative
BOS) is initiated by direct active fibrosis without inflam-
mation and without clearly identified triggers, and does not
respond to azithromycin. This dichotomy in the clinical
spectrum of BOS needs to be confirmed by other clinical
investigators.
If in recent years azithromycin has shown some potential
for prophylaxis and treatment of neutrophilic BOS, the
challenge remains: what kind of treatment can be proposed
for non-responders with fBOS?
Based on the concept that monteluklast, a leukotriene re-
ceptor antagonist in animal models, is able to inhibit pul-
monary as well as hepatic fibrosis, Verleden et al. tested
this agent in 11 patients with BOS without BAL neutrophil-
ia [46]. With the addition of monteluklast they observed
significant attenuation of the decline of FEV1 compared to
placebo, but this strategy now needs to be confirmed by a
larger placebo-controlled randomised study.
Intravenous immunoglobulins (IVIG) are administered as
an immunomodulatory agent for desensitisation protocols
in kidney transplant recipients. Hachem et al. used it in a
prospective study as preemptive antibody-directed therapy
after lung transplantation [47], and showed that IVIG ad-
ministered in combination with rituximab were more effi-
cient in depleting donor specific antibody (DSA) than IVIG
alone.
Aerosolised therapy with corticosteroid was used without
success in BOS. In a prospective randomised trial Iacono et
al. describe how inhaled cyclosporine did not improve the
rate of acute rejection but did improve survival and exten-
ded periods of chronic rejection-free survival [48].
Non-pharmacological therapy
Total lymphoid irradiation (TLI) is a non-pharmacological
immunomodulatory approach that has been first applied
with success in renal transplantation. A few observational
studies have reported TLI of 8 Gy (10 sessions) in patients
with BOS unresponsive to azithromycin. They observed a
slowdown in the decline of FEV1 but this manoeuvre was
only a bridge to retransplantation [49].
Extracorporeal photophoresis was first used in acute graft
rejection. It is thought to induce immunological tolerance
by increasing the level of regulatory T cells rather than in-
ducing overall immunosuppression. Morrell et al. showed a
significant reduction in the rate of decline in lung function
but photopheresis was used as a third-line therapy in addi-
tion to modifications of the maintenance immunosuppress-
ive regimen, initiation of azithromycin and lymphocyte-de-
pleting therapies [50]. The Zurich team has reported the
most extensive experience with photopheresis in lung
transplantation to date [51]. Photopheresis has not yet
gained widespread acceptance due to the burden of this
therapy for the ambulatory patient and the cost with incon-
sistent health insurance coverage.
Clearly the treatment of established BOS, with irreversible
airway fibrosis, is not satisfactory. It is the reason why new
strategies must focus on the prevention of risk factors (im-
mune and non-immune), as well as identification of early
and specific markers of BOS, before pulmonary function
tests have started to decrease.
Conclusion
Lung transplantation is no longer an experimental proced-
ure for a few desperate patients. It remains, however, a
complex therapy with specific challenges starting prior to
surgery and expanding far beyond the first year of survival.
Improvement in the management of these patients will res-
ult from well-designed prospective and controlled studies,
together with data-mining from large scale registries.
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